Windtree Therapeutics Inc

Windtree Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for acute cardiovascular diseases. Its lead candidate, istaroxime, is in Phase 2b trials for acute decompensated heart failure and early cardiogenic shock. The company also develops AEROSURF, Surfaxin, Rostafuroxin, and SERCA2a activators, along with an aPKCi inhibitor. It has strategic alliances and licensing agreements with several partners. Formerly Discovery Laboratories, Inc., it changed its name in April 2016 and is headquartered in Warrington, Pennsylvania.